Upfront Briefing
Jazz got the frontline nod for Ziihera and promptly printed an all-time high, which is what happens when you displace trastuzumab as standard of care in a top-five cancer. Zymeworks, which actually invented the thing, collected $250M and fell 7% — the royalty was in everyone's model, the run-up was not. Elsewhere, ARCH and Population Health built a whole company around a Haisco asset that cleared Chinese IND about ten minutes ago, and Bristol Myers walked away from Cellares after deciding the robots couldn't make Breyanzi at scale.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,677.3 |
0.3% |
12.2% |
| Nasdaq 100 |
29,209.2 |
0.6% |
15.9% |
| Russell 2000 |
3,010.0 |
0.5% |
21.3% |
| Healthcare (XLV) |
175.3 |
0.3% |
12.7% |
| Biotech (XBI) |
169.1 |
3.0% |
39.2% |
| Nasdaq Biotech (NBI) |
7,380.3 |
1.8% |
29.3% |
| Clinical Trials (BBC) |
55.8 |
3.0% |
48.2% |
|
- Biotech led, and led alone: XBI rose 3.00% and BBC 3.01% against XLV's 0.34% and a Russell 2000 up just 0.50%, so this was catalyst-driven mid-cap buying rather than a broad small-cap or defensive-healthcare bid. Jazz closed at an all-time high after the FDA cleared two Ziihera regimens in first-line HER2+ gastroesophageal adenocarcinoma. NBI's 1.82% trailed XBI by 118bp, placing the move below the mega-cap tier.
- Risk appetite improved without help from the front end: the VIX slipped 2.4% to 15.46 and gold eased as semiconductors rebounded from Monday's selloff, but the 10-year backed up 2bp to 4.645% even as TLT gained 1.1% — a long-end bid, not a duration rally. Positioning stayed tight into Nvidia's earnings after Wednesday's bell.
- Market data: U.S. cash close Tuesday, 25 August 2026.
The Big 3
|
1
|
FDA clears Jazz's Ziihera in frontline gastric cancer, triggering a $250M Zymeworks milestone
|
- FDA approved two Ziihera (zanidatamab-hrii) regimens in first-line unresectable locally advanced or metastatic HER2+ gastroesophageal adenocarcinoma — with Tevimbra (tislelizumab) plus chemo for IHC 3+ and IHC 2+/ISH+ regardless of PD-L1 status, and with chemo alone for IHC 3+.
- Why it matters: HERIZON-GEA-01 ran 914 first-line patients and delivered what trastuzumab has not: median OS of 26.4 months on the triplet against 19.2 months on trastuzumab plus chemo, a 28% cut in death risk, with mPFS 12.4 versus 8.1 months. The label spans IHC 3+ and 2+/ISH+ irrespective of PD-L1, so the addressable slice is roughly 20% of a cancer that ranks fifth worldwide. JAZZ closed at an all-time high on a 4% move. Zymeworks banked a $250M milestone and retains 10–20% tiered royalties plus $190M of remaining near-term GEA milestones across the EU, Japan and China — and ZYME still fell 7%. The royalty was already in the model; the equity had run into the date.
- Source: BioPharma Dive
- More: BioSpace; FDA
|
|
2
|
ARCH and Population Health launch Sentivera on a $1.5B Haisco licence
|
- Haisco (SZSE: 002653) granted Sentivera — a NewCo founded by ARCH Venture Partners and Population Health Partners — exclusive rights to a preclinical type 2 inflammation asset outside Greater China, for $75.89M in upfront and equity consideration, up to $1.46B in milestones, and mid-single to low-double-digit tiered royalties.
- Why it matters: Read the headline number carefully — the $1.5B is deal value to Haisco, not capital into Sentivera, whose actual raise is undisclosed. Real cash at signing is $75.89M against $1.46B of contingent value, an upfront ratio of about 5%, which is roughly where China-origin licensing has been clearing all year. What's new is the counterparty type: this is the same ARCH/Population Health pairing that built Metsera and sold it for $10B, now running the playbook on an asset that cleared Chinese IND this month rather than on a Western-discovered molecule. Target and modality are undisclosed, and type 2 inflammation is Dupixent's yard. COINS Act exposure attaches to the sourcing, not the Delaware wrapper.
-
Source:
Endpoints
-
More:
Fierce Biotech; BioSpace
|
| 3 | Bristol Myers ends Cellares deal, prompting reorg |
-
Bristol Myers ended its partnership with Cellares after a comprehensive evaluation concluded the Cell Shuttle platform could not make commercial-scale batches of Breyanzi; Cellares is restructuring and cutting 100 staff per a California WARN filing.
-
Why it matters:
The 2024 agreement was worth up to $380M in upfront and milestones and reserved dedicated Cell Shuttle capacity across the US, Europe and Japan — the single largest validation on the platform, now gone. The layoffs land two months after Cellares closed a $327M Series D, meaning crossover investors funded a growth case that one counterparty has just repriced. For anyone underwriting automated cell-therapy manufacturing, the specific read is worse than a lost contract: BMS didn't switch vendors on price, it walked on technical fit at commercial scale. Sonoma and Cabaletta remain on the platform. Neither carries a Breyanzi-sized proof point, and the next CDMO raise now prices against this.
-
Source:
Endpoints
-
More:
Fierce Pharma
|
Everything Else that broke
- FDA and stakeholders discussed a proposed pilot to speed first-in-human trials in the U.S. — Endpoints
- Implantica won FDA approval for its RefluxStop GERD implant, eight years after the European clearance, opening a U.S. market the medtech has been waiting on since 2018. — Fierce Biotech
- Caliway's CBL-514 cleared Phase 2 in combination with tirzepatide as the SUPREME-01 Phase 3 began enrolling. — PR
- Bausch + Lomb pushed its dry eye drug into Phase 3 despite a mixed Phase 2 readout. — BioSpace
- A new report on Massachusetts biotech showed VC and IPO activity recovering while lab vacancy and headcount kept falling, with thin early-stage funding the open question on the state's rebound. — Fierce Biotech
- BioWorld highlighted Phase III wins for Hutchmed, Taiho and Zai Lab. — BioWorld
- Labcorp launched a hepatitis D reflex test aimed at earlier identification of severe cases. — Fierce Biotech
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Haisco licensed a preclinical type 2 inflammation asset to Sentivera, a new ARCH/Population Health venture, for $75.89M upfront and equity plus up to $1.46B in milestones and tiered royalties, ex-Greater China (see The Big 3). — BioSpace
- Bristol Myers ended its Cellares partnership, triggering a reorganization (see The Big 3). — Endpoints
- Sword Health proposed acquiring Headspace to combine two digital health unicorns. — Endpoints
- BioWorld flagged the Iaso-Medisix acquisition and Tanabe's dersimelagon deal in APAC. — BioWorld
VC / Private Financings
- BioWorld said Abcuro and Renata Medical closed Series D rounds. — BioWorld
- Enginprime Medical closed a Series A round in Asia-Pacific medtech. — BioWorld
IPOs / Follow-Ons
- No notable IPOs or follow-ons in the last 24 hours.
Academic Corner - Nature Medicine published an author correction to the phase 3 SYNCHRONIZE-MASLD survodutide study in adults with obesity and MASLD. — Nature Medicine
|
